Skip to main content
SpringerLink
Log in

The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves’ disease

  • Clinical Research
  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Graves’ disease is an autoimmune disease predominantly seen in females. All types of thyroid cancers may co-exist with Graves’ disease but papillary carcinoma is the most frequent. Vesicular nuclei, nuclear grooves, and papillary formations that may be seen in Graves’ disease may lead the pathologist to an overdiagnosis of papillary carcinoma. The differential diagnosis between a true papillary carcinoma and foci mimicking papillary carcinoma in Graves’ disease may be challenging by light microscopic features only. This study is designed to determine whether CK19 is effective in the discrimination between the true papillary carcinoma of thyroid and foci resembling papillary carcinoma in Graves’ disease. Twenty-five cases with papillary carcinoma and 25 cases with Graves’ disease containing foci resembling papillary carcinoma were included in the study. All 25 cases with papillary carcinoma stained positive with CK19, whereas only six of 25 cases with Graves’ disease showed weak staining, and the remaining 19 cases were completely negative. It is known that CK19 may show faint staining in benign thyroid lesions such as adenomas. Staining pattern with CK19 together with histopathological findings may be helpful in the differential diagnosis between foci mimicking papillary carcinoma and true papillary carcinoma in Graves’ disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosai J. Thyroid gland. In Rosai J, ed. Rosai and Ackerman’s surgical pathology, 9th ed., St. Louis, MO: Mosby, 2004; 515–594.

    Google Scholar 

  2. Daou R. Hyperthyroidism and cancer of the thyroid. Chirurgie. 123(6):604–608, 1998.

    Article  PubMed  CAS  Google Scholar 

  3. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. Atlas of thyroid pathology, 3rd series, fascicle 5. Washington DC: Armed Forces Institute of Pathology, 1992.

    Google Scholar 

  4. Erkilic S, Aydin A, Kocer NE. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Path 13(3):207–211, 2002.

    Article  CAS  Google Scholar 

  5. Gabriele R, Letizia C, Borghese M, et al. Thyroid cancer in patients with hyperthyroidism. Horm Res 60(2):79–83, 2003.

    Article  PubMed  CAS  Google Scholar 

  6. Miettinen M, Fetsch JF. Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis. Hum Pathol 31:1062–1067, 2000.

    Article  PubMed  CAS  Google Scholar 

  7. Judkins AR, Roberts SA, Livolsi VA. Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors. Hum Pathol 30:1373–1376, 1999.

    Article  PubMed  CAS  Google Scholar 

  8. Schelfout LJ, Van Muijen GN, Fleuren GJ. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Am J Clin Pathol 92:654–658, 1989.

    Google Scholar 

  9. Bennett WP, Bhan AK, Vickery AL Jr. Keratin expression as a diagnostic adjunct in thyroid tumors with papillary architecture. Lab Invest 58:9A, 1988.

    Google Scholar 

  10. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 116:696–702, 2001.

    Article  PubMed  CAS  Google Scholar 

  11. Miettinen M, Fransilla KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol 31(9):1139–1145, 2000.

    Article  PubMed  CAS  Google Scholar 

  12. Schroder S, Wodzynski A, Padberg B. Cytokeratin expression of benign and malignant epithelial thyroid gland tumors: an immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies. Pathology 17(6):425–432, 1996.

    Article  CAS  Google Scholar 

  13. Baloch ZW, Abraham S, Roberts S, LiVolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and diagnostic utility. Hum Pathol 30:1166–1171, 1999.

    Article  PubMed  CAS  Google Scholar 

  14. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 14(1):55–60, 2003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Pathology, Gaziantep University, Gaziantep, Turkey

    Suna Erkiliç MD & N. Emrah Koçer MD

Authors
  1. Suna Erkiliç MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Emrah Koçer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suna Erkiliç MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erkiliç, S., Koçer, N.E. The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves’ disease. Endocr Pathol 16, 63–66 (2005). https://doi.org/10.1385/EP:16:1:063

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/EP:16:1:063

Key Words

Search

Navigation